230 related articles for article (PubMed ID: 26553672)
1. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
[TBL] [Abstract][Full Text] [Related]
2. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
[TBL] [Abstract][Full Text] [Related]
3. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
4. From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
Aguado MT; Jodar L; Granoff D; Rabinovich R; Ceccarini C; Perkin GW
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S391-5. PubMed ID: 26553665
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
Dellepiane N; Akanmori BD; Gairola S; Jadhav SS; Parker C; Rodriguez C; Srivastava S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S428-33. PubMed ID: 26553671
[TBL] [Abstract][Full Text] [Related]
6. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
[TBL] [Abstract][Full Text] [Related]
7. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
LaForce FM; Djingarey M; Viviani S; Preziosi MP
Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
[TBL] [Abstract][Full Text] [Related]
9. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
[TBL] [Abstract][Full Text] [Related]
10. Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.
Alderson MR; LaForce FM; Sobanjo-Ter Meulen A; Hwang A; Preziosi MP; Klugman KP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S274-S278. PubMed ID: 31671447
[TBL] [Abstract][Full Text] [Related]
11. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
; Altmann D; Aseffa A; Bash M; Basta N; Borrow R; Broome C; Caugant D; Clark T; Collard JM; Djingarey M; Goldblatt D; Greenwood B; Griffiths U; Hajjeh R; Hassan-King M; Hugonnet S; Kimball AM; LaForce M; MacLennan C; Maiden MC; Manigart O; Mayer L; Messonnier N; Moisi J; Moore K; Moto DD; Mueller J; Nascimento M; Obaro S; Ouedraogo R; Page AL; Perea W; Pluschke G; Preziosi MP; Sow S; Stephens D; Stuart J; Thomson M; Tiendrebeogo S; Trape JF; Vernet G
Vaccine; 2013 Mar; 31(11):1453-7. PubMed ID: 23273967
[TBL] [Abstract][Full Text] [Related]
12. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
13. Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool.
Cibrelus L; Lingani C; Fernandez K; Djingarey MH; Perea WA; Hugonnet S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S442-50. PubMed ID: 26553673
[TBL] [Abstract][Full Text] [Related]
14. The burden of meningococcal meningitis in the African Meningitis Belt, from 2009 to 2014: a trend analysis.
Jaca A; Wiyeh AB; Sambala EZ; Wiysonge CS
Pan Afr Med J; 2021; 39():57. PubMed ID: 34422180
[TBL] [Abstract][Full Text] [Related]
15. Technical Development of a New Meningococcal Conjugate Vaccine.
Frasch CE; Kapre SV; Lee CH; Préaud JM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S404-9. PubMed ID: 26553667
[TBL] [Abstract][Full Text] [Related]
16. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.
Trotter CL; Lingani C; Fernandez K; Cooper LV; Bita A; Tevi-Benissan C; Ronveaux O; Préziosi MP; Stuart JM
Lancet Infect Dis; 2017 Aug; 17(8):867-872. PubMed ID: 28545721
[TBL] [Abstract][Full Text] [Related]
17. Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa.
Berlier M; Barry R; Shadid J; Sirica C; Brunier A; Hasan H; Bouma E
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S451-8. PubMed ID: 26553674
[TBL] [Abstract][Full Text] [Related]
18. [Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine].
Nicolas P
Med Sante Trop; 2012; 22(3):246-58. PubMed ID: 23186941
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal carriage in the African meningitis belt.
MenAfriCar Consortium
Trop Med Int Health; 2013 Aug; 18(8):968-78. PubMed ID: 23682910
[TBL] [Abstract][Full Text] [Related]
20. Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.
Idoko OT; Diallo A; Sow SO; Hodgson A; Akinsola A; Diarra B; Haidara FC; Ansah PO; Kampmann B; Bouma E; Preziosi MP; Enwere GC
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S416-21. PubMed ID: 26553669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
